Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response
Miles Sparrow, Konstantinos Papamichael, Mark G. Ward, et al.
Journal of Crohn s and Colitis (2019) Vol. 14, Iss. 4, pp. 542-556
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease
Adam S. Cheifetz, María T. Abreu, Waqqas Afif, et al.
The American Journal of Gastroenterology (2021) Vol. 116, Iss. 10, pp. 2014-2025
Open Access | Times Cited: 151
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
Konstantinos Papamichael, Waqqas Afif, David Drobne, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 2, pp. 171-185
Open Access | Times Cited: 109
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
Giuseppe Privitera, Daniela Pugliese, Loris Riccardo Lopetuso, et al.
Therapeutic Advances in Gastroenterology (2021) Vol. 14
Open Access | Times Cited: 55
Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Jan Marsal, Manuel Barreiro–de Acosta, Irina Blumenstein, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 46
Challenges in IBD Research 2024: Precision Medicine
Sana Syed, Brigid S. Boland, Lauren T Bourke, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. Supplement_2, pp. S39-S54
Open Access | Times Cited: 9
Effectiveness and Safety of Ustekinumab Intensification at 90 mg Every 4 Weeks in Crohn’s Disease: A Multicentre Study
Mathurin Fuméry, Laurent Peyrin‐Biroulet, Stéphane Nancey, et al.
Journal of Crohn s and Colitis (2020) Vol. 15, Iss. 2, pp. 222-227
Open Access | Times Cited: 50
Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis
Konstantinos Papamichael, Niels Vande Casteele, Jenny Jeyarajah, et al.
The American Journal of Gastroenterology (2020) Vol. 116, Iss. 5, pp. 1007-1014
Open Access | Times Cited: 50
Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD
Nurulamin M Noor, Paula Sousa, Stéphane Paul, et al.
Inflammatory Bowel Diseases (2021) Vol. 28, Iss. 8, pp. 1254-1264
Open Access | Times Cited: 43
Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: “early therapeutic drug monitoring of adalimumab”
Patricia Ortiz-Fernández, Carles Iniesta Navalón, Elena Urbieta-Sanz, et al.
Clinical Rheumatology (2025)
Open Access
Redox‐Induced Stabilization of AMBRA1 by USP7 Promotes Intestinal Oxidative Stress and Colitis Through Antagonizing DUB3‐Mediated NRF2 Deubiquitination
Weimin Xu, Zhebin Hua, W. Yaosheng, et al.
Advanced Science (2025)
Open Access
Laboratory Tests in Inflammatory Bowel Disease: An Evidence-Based Approach to Daily Practice
Katelin Durham, Tyler Atagozli, David E. Elliott, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 491-491
Open Access
Mapping the Evolution of IBD Treatment: A Bibliometric Study on Biologics and Small Molecules
Huibo Li, Jia Wang, Yang Hu, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 312-312
Open Access
The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides
Gábor Tajti, Dorothy C.C. Wai, György Panyi, et al.
Biochemical Pharmacology (2020) Vol. 181, pp. 114146-114146
Closed Access | Times Cited: 46
Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
Giuseppe Privitera, Daniela Pugliese, Gian Ludovico Rapaccini, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 4, pp. 853-853
Open Access | Times Cited: 32
Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)
Konstantinos Papamichael, Vipul Jairath, Guangyong Zou, et al.
BMJ Open (2022) Vol. 12, Iss. 4, pp. e057656-e057656
Open Access | Times Cited: 25
Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease
Xavier Roblin, Stéphane Nancey, Konstantinos Papamichael, et al.
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 5, pp. 679-685
Closed Access | Times Cited: 15
Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Krishneel Dutt, Abhinav Vasudevan
Medicina (2024) Vol. 60, Iss. 2, pp. 250-250
Open Access | Times Cited: 4
Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access | Times Cited: 4
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 10
Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology
Konstantinos Papamichael, Adam S. Cheifetz
Current Opinion in Rheumatology (2020) Vol. 32, Iss. 4, pp. 371-379
Open Access | Times Cited: 27
Biologics: how far can they go in Crohn’s disease?
Katie A. Dunleavy, Darrell S. Pardi
Gastroenterology report (2022) Vol. 10
Open Access | Times Cited: 17
Approach to loss of response to advanced therapies in inflammatory bowel disease
Nikil Vootukuru, Abhinav Vasudevan
World Journal of Gastroenterology (2024) Vol. 30, Iss. 22, pp. 2902-2919
Open Access | Times Cited: 2
Multi-utility of therapeutic drug monitoring in inflammatory bowel diseases
Camilla de Almeida Martins, Karoline Soares Garcia, Natália Sousa Freitas Queiroz
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 13
Harnessing the Power of Precision Medicine and Novel Biomarkers to Treat Crohn’s Disease
Ofra Kriger-Sharabi, Uri Kopylov
Journal of Clinical Medicine (2023) Vol. 12, Iss. 7, pp. 2696-2696
Open Access | Times Cited: 7
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations
Ole Haagen Nielsen, Alexander Hammerhøj, Mark Ainsworth, et al.
Drugs (2024)
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top